Health Equities and Variations in Advanced Prostate Cancer Care Podcast (2023)

Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has produced a series of podcasts to update urologists on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This activity will focus on the following topic: 

Health Equities and Variations in Advanced Prostate Cancer Care 

 

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from: 

Myovant Sciences LTD
Pfizer, Inc.

Target Audience

  • Urologists
  • Advanced Practice Providers (APPs)

Learning Objectives

At the conclusion of these activities, participants will be able to:

  1. Identify the impact of race and cultural barriers for ethnic minorities on medical clinical care specific to advanced prostate cancer.
  2. Evaluate financial toxicity as a barrier to optimal patient care specific to advanced prostate cancer.
  3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Course opens: 
02/22/2023
Course expires: 
02/22/2024
Rating: 
0

EDUCATION COUNCIL DISCLOSURES

PDF icon Education Council Disclosures_2022.pdf

COI REVIEW WORK GROUP DISCLOSURES

PDF icon COI Review Work Group Disclosures_2023.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Moderator(s)

Jay Raman, MD, FACS

has a financial relationship (Stock Options (General Urology)) with United Medical Systems, Inc.;.
has a financial relationship (Stock Options (Endourology/Stone Disease)) with American Kidney Stone Management;.
Podcast Co-Host(s)

Chad Ritch, MD, MBA

has a financial relationship (Consultant or Advisor (Oncology)) with mIR Scientific;.

Kristen Scarpato, MD,FACS,MPH

has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Photocure;.
has a financial relationship (Consultant or Advisor (Oncology)) with CxBladder;.
has a financial relationship (Consultant or Advisor (Oncology)) with Optum;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 0.50 hours

Release Date: February, 2023
Expiration Date: February, 2024

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Please login or register to take this course.